据央视新闻，12月13日，全国医疗保障工作会议在北京召开，国家医保局在会议上发布多项数据和措 施。 2026年，国家医保局将发布按病种付费3.0版分组方案。全面推行按季或按月特例单议评审，支持新药 耗新技术临床使用和疑难重症救治。加大医保基金预付力度，全面推进医保基金即时结算，探索按季度 清算。全面完成40批立项指南编制工作，实现医疗服务价格项目全国基本统一。 力争基本实现政策范围内分娩个人"无自付" 国家医保局表示，为积极适应人口发展战略，2026年将持续推动生育保险和长期护理保险发展，力争全 国基本实现政策范围内分娩个人"无自付"。 我国建立完善居民医保高血压、糖尿病"两病"门诊用药保障机制。健全重特大疾病医疗保险和救助制 度。5年来大病保险累计惠及超3.4亿人次。建立完善防范化解因病致贫返贫风险的长效机制，加强困难 群众就医服务管理，支持慈善等社会力量参与医疗救助，医疗救助惠及11.89亿人次，农村困难群众政 策范围内报销比例超90%。 医保大力支持医疗机构发展 2025年我国持续深化医保支付方式改革，促进医疗卫生事业和医药行业发展，按病种付费从试点起步实 现全面覆盖。 2025年，国家医保局制定实施按 ...

人民网北京12月13日电 （记者乔业琼）据国家医保局官网消息，今日，全国医疗保障工作会议在 北京召开。会议明确，2026年，将发布按病种付费3.0版分组方案。全面推行按季或按月特例单议评 审，支持新药耗新技术临床使用和疑难重症救治。支持基层医疗卫生机构健康发展，促进分级诊疗。加 大医保基金预付力度，全面推进医保基金即时结算，探索按季度清算。全面完成40批立项指南编制工 作，实现医疗服务价格项目全国基本统一。 ...

每经AI快讯，据国家医保局消息，12月13日，全国医疗保障工作会议在北京召开。会议要求，2026年 要优化医保支付结算机制，促进医疗事业健康发展。发布按病种付费3.0版分组方案。全面推行按季或 按月特例单议评审，支持新药耗新技术临床使用和疑难重症救治。支持基层医疗卫生机构健康发展，促 进分级诊疗。加大医保基金预付力度，全面推进医保基金即时结算，探索按季度清算。全面完成40批立 项指南编制工作，实现医疗服务价格项目全国基本统一。 （文章来源：每日经济新闻） ...

Core Insights - Zhengzhou has implemented a groundbreaking medical insurance fund instant settlement reform, significantly reducing the reimbursement time from an average of 30 days to just 1 day, enhancing cash flow for hospitals [1][2] - The reform integrates the settlement process into a streamlined "instant acceptance and approval" model, eliminating previous steps and improving efficiency [2] - A new intelligent reconciliation platform has been launched, facilitating real-time data synchronization between medical institutions and insurance agencies, thus ensuring accurate and timely fund allocation [2][3] Group 1 - The instant settlement reform was initiated by Zhengzhou Medical Insurance Bureau, making it the first in the country to adopt such a system [2] - The previous "post-payment" model placed a heavy financial burden on medical institutions, leading to slow fund circulation [2] - The new process includes a scientific mechanism to ensure fund security while enhancing efficiency, with 70% of inpatient expenses being audited and paid promptly [2] Group 2 - Since the system's launch on January 15, over 251 designated medical institutions have participated, completing more than 27,000 settlements and disbursing a total of 11.792 billion yuan [3] - The initiative aligns with national goals to improve the coordination of medical, insurance, and pharmaceutical services, aiming for further reforms such as direct and synchronous settlements [3]

Policy Developments - The National Healthcare Security Administration (NHSA) announced that by the end of 2025, all coordinated areas in the country must implement instant settlement for medical insurance funds [2] - By the end of 2026, instant settlement funds should account for over 80% of the local medical insurance fund's monthly settlement funds, covering various medical expenses [2] Industry Developments - Jiangxi Province is promoting the development of modern seed industry for traditional Chinese medicine, focusing on the protection of medicinal material resources and the establishment of breeding bases [3] - The company Jiuzhoutong received approval for the market launch of the chemical raw material drug, Glycopyrrolate, which will enhance its product line and market competitiveness [5] - Sichuan Shuangma's subsidiary obtained approval for the chemical raw material drug, Leuprolide Acetate, further strengthening its competitive advantage in the domestic raw material drug sector [6] Financial Reports - Guobang Pharmaceutical reported a 23.17% year-on-year increase in net profit for Q3, despite a 5.39% decline in revenue [8] Investment Activities - OxTium Technology completed several million yuan in angel+ round financing, led by Sequoia China Seed Fund [11] Clinical Research - Eli Lilly announced positive results from two Phase 3 clinical trials for orforglipron, showing significant improvements in blood sugar control and weight loss for type 2 diabetes patients [14] Shareholder Actions - Kangtai Medical announced that major shareholder Wang Guili reduced her holdings by 4.24 million shares, decreasing her ownership to 8.95% [17]

Group 1 - The Ministry of Commerce expressed strong dissatisfaction and opposition to the U.S. measures against China, urging for corrections and dialogue based on mutual respect [1] - The National Healthcare Security Administration issued a notice to implement instant settlement reforms for medical insurance funds by the end of 2025, aiming for 80% of local medical insurance fund settlements to be instant by the end of 2026 [1] - The People's Bank of China conducted a 236 billion yuan reverse repurchase operation, maintaining the interest rate at 1.40%, resulting in a net withdrawal of 376 billion yuan for the day [1] Group 2 - The Ministry of Industry and Information Technology launched a special action to enhance computing power access networks, aiming for 70% coverage of millisecond latency in urban areas by 2027 [2] - The State Administration for Market Regulation released a draft regulation focusing on food safety responsibilities in the takeaway industry, requiring transparency in food preparation processes [2] - China's foreign trade showed resilience in the first three quarters, with plans to enhance support for foreign trade enterprises through financial and policy measures [2] Group 3 - Guangdong's foreign trade in the first three quarters reached 7.02 trillion yuan, a 3.8% increase year-on-year, accounting for 20.9% of the national total [3] - The "Linglong No. 1" modular small reactor completed its cold performance test, expected to generate 1 billion kWh annually, reducing CO2 emissions by approximately 880,000 tons [3] - There are rumors about the establishment of a polysilicon storage platform, but industry experts have indicated that these rumors are unfounded [3] Group 4 - Spot gold prices reached a historical high of $4,240 per ounce, with a year-to-date increase of nearly 60% [4] - Several unprofitable companies have initiated their IPO processes, including He Yuan Bio and Xi'an Yicai, marking a significant trend in the market [4] - A record 13 companies in the A-share market have triggered mandatory delisting indicators due to major violations, with 8 already delisted [4] Group 5 - Apple is preparing to launch a new MacBook Pro with a touch screen and M6 series chip, expected to be released in late 2026 or early 2027, potentially at a higher price point [5] - Fuyao Glass announced a leadership change with the resignation of Chairman Cao Dewang, who will remain involved in the company [6] - TSMC reported Q3 revenue of 989.92 billion NTD, a 30.3% year-on-year increase, with net profit reaching a record high [6] Group 6 - Tesla's CEO Elon Musk's high compensation case is under judicial review, with efforts to restore a $56 billion compensation plan [7] - The U.S. government is facing a prolonged shutdown, now entering its 17th day, affecting economic data releases and overall economic stability [8] Group 7 - Guangdong's humanoid robot industry is gaining momentum due to capital investment and favorable policies, but challenges remain in core component autonomy and application development [9] - Nestlé plans to cut approximately 16,000 jobs globally over the next two years, aiming to save 1 billion Swiss francs annually by 2027 [10]

Group 1: Sustainable Reporting - A total of 1869 listed companies have disclosed their 2024 sustainability reports, achieving an overall disclosure rate of 34.7%, which is an increase of approximately 10 percentage points compared to the previous two years [1][2] - By the end of last year, one-third of companies in the Shanghai and Shenzhen stock markets had improved their MSCI ESG ratings [2] - Although the number of companies required to disclose is not large, their market capitalization accounts for over half of the entire market [2] - Companies mandated to disclose will start doing so in 2026, with 95% of them having already disclosed sustainability or social responsibility reports ahead of schedule [2] Group 2: Service Consumption Expansion - The Ministry of Commerce plans to focus on three areas to continuously promote the steady expansion of service consumption [2] - The first area is to cultivate new growth points for service consumption by improving support policies and addressing bottlenecks [2] - The second area involves innovating diverse consumption scenarios, promoting pilot projects, and integrating various sectors such as commerce, tourism, and culture [2] - The third area is to optimize service supply, emphasizing quality improvements in services for the elderly and children, and enhancing urban convenience [2] Group 3: Company Performance - Shijia Photon reported a net profit of 299 million yuan for the first three quarters, representing a year-on-year increase of 727.74%, driven by the rapid growth of the data communication market and increased customer recognition [5] - Rongzhi Rixin expects a net profit of 26.4 million to 27.4 million yuan for the first three quarters, reflecting a year-on-year increase of 871.3% to 908.09% [6] - Guangku Technology anticipates a net profit of 109.72 million to 120.89 million yuan for the first three quarters, indicating a year-on-year growth of 97% to 117% [7] Group 4: Corporate Transactions - Good Products announced the termination of the transfer of control to Changjiang Guomao, with the controlling shareholder remaining Ningbo Hanyi [8] - Zhongjin Company received approval from the China Securities Regulatory Commission to publicly issue technology innovation corporate bonds totaling no more than 10 billion yuan [7] - Huada Technology plans to acquire 100% of Huayi Microelectronics through a combination of stock issuance and cash payment, with no change in control expected [7]

Core Points - The National Healthcare Security Administration (NHSA) aims to alleviate the financial burden on medical institutions by implementing real-time settlement across all coordinated areas by the end of 2025 [1] - By the end of 2026, it is expected that real-time settlement funds will account for over 80% of the monthly settlement funds of local healthcare insurance funds [1] - The initiative will cover various medical expenses, including outpatient services, chronic disease treatments, hospitalizations, maternity care, and pharmacy purchases, with plans to gradually include cross-regional medical expenses [1] Group 1 - The NHSA has issued a notice to promote the comprehensive advancement of real-time settlement reform, aiming for all coordinated areas to implement this by the end of 2025 [1] - By the end of 2026, at least 80% of designated medical institutions should be able to provide real-time settlement services [1] - The initiative encourages the inclusion of retail pharmacies in the real-time settlement framework [1] Group 2 - The notice mandates the standardization of fund disbursement mechanisms, requiring provincial healthcare departments to guide designated medical institutions to report medical expenses by the 10th of the following month [2] - Localities are encouraged to enhance the efficiency of real-time settlement processes through information technology, aiming to reduce the settlement cycle [2] - Funds should be disbursed within 20 working days after the reporting deadline, with a goal of completing payments by the end of the following month [2]

Group 1: Healthcare Policy and Regulations - The National Health Commission issued the "Chikungunya Fever Diagnosis and Treatment Plan (2025 Edition)" to improve medical treatment standards for Chikungunya fever [1] - The National Medical Insurance Administration released the "Basic Medical Insurance Fund Instant Settlement Handling Procedures (Trial)" to streamline the settlement process for medical expenses [2] - The National Medical Insurance Administration established a new pricing mechanism for innovative drugs and medical devices, including specific pricing for brain-computer interface technologies [3] Group 2: Drug and Vaccine Approvals - Hengrui Medicine's subsidiaries received clinical trial approval for three drug candidates, including SHR-8068, a fully human anti-CTLA-4 monoclonal antibody [4] - Laika Pharmaceuticals announced FDA approval for clinical trials of LAE103, a monoclonal antibody targeting ActRIIB for muscle-related diseases [5] - Beijing Kexing's combined hepatitis A and B vaccine received re-registration approval, becoming the only approved combined vaccine in China [7] Group 3: Clinical Trial Results - Yahui Pharmaceuticals reported positive preliminary results from the Phase Ib clinical trial of APL-1401 for moderate to severe active ulcerative colitis [8] Group 4: Financial Performance - Hendi Pharmaceuticals reported a 72.92% year-on-year decrease in net profit for the first half of the year, with revenue of 235 million yuan, down 2.93% [10] Group 5: Mergers and Acquisitions - Lidman Biochemical is planning to acquire up to 70% of Xiangrui Biological's shares, a company focused on in vitro diagnostic reagents and human vaccines [11] Group 6: Industry Developments - Yuanda Pharmaceutical secured exclusive agency rights for the medical-grade Ge-68/Ga-68 generator in China, enhancing its position in the nuclear medicine sector [13] - Shenyang Biological signed a cooperation agreement with Lanzhou Veterinary Research Institute to develop multi-valent vaccines for livestock [15] - Illumina launched a new version of its flagship cancer research testing solution, TruSight Oncology 500, enhancing capabilities for comprehensive genomic profiling [16] - Siemens Healthineers and Prisma Health deepened their partnership to improve cancer care in South Carolina and Tennessee, with Prisma investing $50 million [17]

Core Viewpoint - Shandong province is enhancing the quality and efficiency of medical insurance services to strengthen health security for the public, focusing on reforms in outpatient chronic disease cross-province settlement, instant settlement with designated medical institutions, and long-term care insurance [2][3]. Group 1: Outpatient Chronic Disease Cross-Province Settlement - As of June 30, 2023, Shandong has 2,859 medical institutions supporting the new outpatient chronic disease cross-province direct settlement, with a total of 26,000 cases settled, reducing patient out-of-pocket expenses by 5.66 million yuan [2]. - In 2022, Shandong was the first in the country to implement cross-province direct settlement for five outpatient chronic diseases, achieving a direct settlement rate exceeding 90% [2]. Group 2: Instant Settlement with Designated Medical Institutions - Since January 2023, Shandong has fully launched the instant settlement reform, reducing the settlement cycle from over a month to within 15 working days, benefiting over 33,000 designated medical institutions [3]. - By the end of May 2023, 34.67 million medical expenses had been reimbursed through a "one-stop settlement" platform, benefiting 6.27 million individuals [3]. Group 3: Long-term Care Insurance - Shandong has achieved full coverage of employee long-term care insurance and initiated resident long-term care insurance in 2022, with 54.44 million people insured and 650,000 individuals receiving care benefits as of May 2023 [4]. - The province has also implemented cross-province payment and online application for long-term care insurance, with nearly 1,500 individuals receiving over 20 million yuan in benefits while outside their home province [4].